Open access
Open access
Powered by Google Translator Translator

Chest Medicine

A randomized controlled trial explored the safety and tolerability of Sulthiame in sleep apnea.

18 Apr, 2022 | 10:08h | UTC

A Randomized Controlled Trial Exploring Safety and Tolerability of Sulthiame in Sleep Apnea – American Journal of Respiratory and Critical Care Medicine

News Release: Drug reduced frequency of breathing pauses in sleep apnea – University of Gothenburg

 

Commentary on Twitter

 

Cross-sectional study: evaluating prediction models of sleep apnea from smartphone-recorded sleep breathing sounds.

18 Apr, 2022 | 09:44h | UTC

Evaluating Prediction Models of Sleep Apnea From Smartphone-Recorded Sleep Breathing Sounds – JAMA Otolaryngology-Head & Neck Surgery (link to abstract – for full-text)

 

Commentary on Twitter

 

Incidental discovery of interstitial lung disease: diagnostic approach, surveillance and perspectives.

18 Apr, 2022 | 09:36h | UTC

Incidental discovery of interstitial lung disease: diagnostic approach, surveillance and perspectives – European Respiratory Review

 

A nationwide observational analysis in Israel showed a fourth dose of the Pfizer vaccine may reduce the short-term risk of Covid-19–related outcomes.

14 Apr, 2022 | 08:51h | UTC

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting – New England Journal of Medicine

Editorial: Covid-19 Boosters — Where from Here?

Related:

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines.

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Commentary on Twitter

 

Covid-19: What is the evidence for the antiviral molnupiravir?

14 Apr, 2022 | 08:47h | UTC

Covid-19: What is the evidence for the antiviral molnupiravir? – The BMJ

 

The Lancet Series: Origins of chronic obstructive pulmonary disease.

14 Apr, 2022 | 08:38h | UTC

Homepage: Origins of chronic obstructive pulmonary disease – The Lancet Respiratory Medicine (free registration required for all articles)

Genetics of chronic obstructive pulmonary disease: understanding the pathobiology and heterogeneity of a complex disorder

Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment

Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene–environment interactions across the lifespan

GETting to know the many causes and faces of COPD

COPD, smoking, and social justice

 

Commentary on Twitter (thread – click for more)

 

Review: Diagnosis and treatment of pulmonary arterial hypertension.

13 Apr, 2022 | 10:58h | UTC

Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review – JAMA (free for a limited period)

Audio Clinical Review: Diagnosis and Treatment of Pulmonary Arterial Hypertension – JAMA

 

Commentary on Twitter

 

Drug resistant TB – latest developments in epidemiology, diagnostics and management.

13 Apr, 2022 | 10:09h | UTC

Drug resistant TB – latest developments in epidemiology, diagnostics and management – International Journal of Infectious Diseases

Related:

Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.

WHO Consolidated Guidelines on Drug-resistant Tuberculosis Treatment

Randomized Trial: 9-month Treatment for Multi-drug Resistant TB is as Effective as 24-month Treatment

Canadian Tuberculosis Standards – 8th Edition.

Guideline: Treatment of Drug-Resistant Tuberculosis

NICE Guideline: Tuberculosis

The Lancet Commission: Management of Multidrug-resistant and Incurable Tuberculosis

Regimens to Treat Multidrug-resistant Tuberculosis: Past, Present and Future Perspectives

 

More data suggests the Omicron variant causes milder disease compared to the Delta variant.

12 Apr, 2022 | 09:49h | UTC

Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study – The Lancet

Commentary: Covid-19: Symptomatic infection with omicron variant is milder and shorter than with delta, study reports – The BMJ

Related:

Another study suggests a lower risk of hospitalization and death from infection with SARS-CoV-2 Omicron variant vs. Delta.

Perspective: Challenges in inferring intrinsic severity of the SARS-CoV-2 Omicron variant.

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa.

Cohort Study: Incidence rates and clinical outcomes of SARS-CoV-2 infection with the Omicron and Delta variants in children younger than 5 years in the US.

[Preprint] SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters.

[Preprint] Study showed reduced clinical severity of Covid-19 patients admitted to hospitals in Gauteng, South Africa, during the Omicron-dominant fourth wave – “any combination of a less-virulent virus, comorbidities, high immunity from prior infection(s) or vaccination may be important contributors to this clinical presentation”.

Early data from South Africa hints Omicron variant may cause less severe Covid, but more research is needed.

Too early to tell, but preliminary information from doctors in South Africa suggests the new Covid variant Omicron may be associated with less severe disease.

 

Empyema: ED presentation, evaluation, and management.

12 Apr, 2022 | 08:44h | UTC

Empyema: ED Presentation, Evaluation, and Management – emDocs

 

Review: Drug-induced interstitial lung disease.

12 Apr, 2022 | 08:29h | UTC

Drug-induced interstitial lung disease – European Respiratory Review

Related: Systematic Review: Drug-Induced Interstitial Lung Disease

 

Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment.

12 Apr, 2022 | 08:27h | UTC

Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment – ESMO Open

 

RCT: Prophylactic Penehyclidine inhalation for prevention of postoperative pulmonary complications in high-risk patients.

12 Apr, 2022 | 08:18h | UTC

Prophylactic Penehyclidine Inhalation for Prevention of Postoperative Pulmonary Complications in High-risk Patients: A Double-blind Randomized Trial – Anesthesiology

 

Clinical update on COVID-19 for the emergency and critical care clinician: Medical management.

11 Apr, 2022 | 02:00h | UTC

Clinical update on COVID-19 for the emergency and critical care clinician: Medical management – American Journal of Emergency Medicine

 

RCT: Effect of Gram Stain–Guided initial antibiotic therapy on clinical response in patients with ventilator-associated pneumonia.

11 Apr, 2022 | 01:36h | UTC

Effect of Gram Stain–Guided Initial Antibiotic Therapy on Clinical Response in Patients With Ventilator-Associated Pneumonia: The GRACE-VAP Randomized Clinical Trial – JAMA Network Open

Commentary: Can Gram Stains Guide Antibiotics for Pneumonia in Critical Care? – Medscape (free registration required)

 

Commentary on Twitter

 

Clinical care of severe acute respiratory infections – Tool kit (COVID-19 adaptation, update 2022).

11 Apr, 2022 | 01:45h | UTC

Clinical care of severe acute respiratory infections – Tool kit – World Health Organization

 

Commentary on Twitter (thread – click for more)

 

RCT: Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough.

11 Apr, 2022 | 01:22h | UTC

Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials – The Lancet (link to abstract – $ for full-text)

 

Commentary on Twitter

 

RCT: In critically ill children requiring noninvasive respiratory support following extubation, high-flow nasal cannula therapy was NOT noninferior to CPAP, resulting in increased time to liberation from respiratory support.

8 Apr, 2022 | 11:07h | UTC

Effect of High-Flow Nasal Cannula Therapy vs Continuous Positive Airway Pressure Following Extubation on Liberation From Respiratory Support in Critically Ill Children: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Selecting Intermediate Respiratory Support Following Extubation in the Pediatric Intensive Care Unit – JAMA (free for a limited period)

News Release: Trial identifies most effective breathing support for children in intensive care – Imperial College London

 

Commentary on Twitter

 

M-A: Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia.

8 Apr, 2022 | 10:50h | UTC

Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis – International Journal of Infectious Diseases

Related:

Case series of Thrombosis with Thrombocytopenia Syndrome after Covid-19 vaccination in the US.

Review: Vaccine-induced immune thrombotic thrombocytopenia.

Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.

Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)

 

M-A: Diagnostic performance of CO-RADS for Covid-19.

8 Apr, 2022 | 10:31h | UTC

Diagnostic performance of CO-RADS for COVID-19: a systematic review and meta-analysis – European Radiology

Related: CO-RADS – A categorical CT assessment scheme for patients with suspected COVID-19: definition and evaluation – Radiology

 

Brief Review: How to do lung ultrasound.

8 Apr, 2022 | 09:52h | UTC

How to do lung ultrasound – European Heart Journal – Cardiovascular Imaging

 

Study finds increased risk of pulmonary embolism up to 110 days after COVID-19.

7 Apr, 2022 | 10:06h | UTC

Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study – The BMJ

News Release: Study finds increased risk of serious blood clots up to six months after COVID-19 – BMJ

Editorial: Thromboembolism and bleeding after covid-19

Commentary: Covid: Blood clot risk higher for six months after having virus – BBC

 

M-A: Fluvoxamine for outpatient management of COVID-19 to prevent hospitalization.

7 Apr, 2022 | 09:55h | UTC

Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis – JAMA Network Open

Commentary: Common Antidepressant Likely Cuts Risk Of Covid Hospitalization, Study Finds – Forbes

Related:

Short Review: Fluvoxamine for symptomatic outpatients with COVID-19.

Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.

Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

 

Commentary on Twitter

 

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines.

7 Apr, 2022 | 10:00h | UTC

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines –
European Centre for Disease Prevention and Control

Related:

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Commentary on Twitter (thread – click for more)

 

Pragmatic RCT: In outpatients with Covid-19, the addition of pulse oximetry for monitoring did not improve outcomes compared to subjective assessments of dyspnea alone.

7 Apr, 2022 | 09:58h | UTC

Pulse Oximetry for Monitoring Patients with Covid-19 at Home — A Pragmatic, Randomized Trial – New England Journal of Medicine

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.